Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis

Stock Information for Channel Therapeutics Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Channel Therapeutics Corporation

Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA(TM) Platform for Rapid On-Site DNA and Gene Synthesis
Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis
Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market
Telesis Bio Reports Second Quarter and First Half 2024 Financial Results
Telesis Bio Reports First Quarter 2024 Financial Results
Telesis Bio Announces Reverse Stock Split
Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadership
Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.